Method of administering phospholipid dispersions
September 18, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3745991 Lung surfactant compositions Recombinant alveolar surfactant protein Lung surfactant compositions Intermittent signal actuated nebulizer Inhalation anaesthesia equipment Recombinant DNA sequence encoding alveolar surfactant protein Recombinant DNA sequence encoding Alveolar Surfactant Protein SAP-6-Val proteins and methods Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy InventorsAssigneeApplicationNo. 948144 filed on 09/18/1992US Classes:128/200.24, RESPIRATORY METHOD OR DEVICE128/200.14, LIQUID MEDICAMENT ATOMIZER OR SPRAYER128/203.26, Means for heating treating agent, respiratory gas, or mixture thereof514/78LecithinsExaminersPrimary: Burr, Edgar S.Assistant: Raciti, Eric P. Attorney, Agent or FirmForeign Patent References
International ClassesA61K 037/02A61M 011/00 Foreign Application Priority Data1991-09-19 GBAbstractA method of administering a surfactant dispersion to the lungs of a patient in need of such treatment is disclosed. The method comprises heating the dispersion and nebulizing the heated dispersion to produce respirable surfactant particles. The respirable surfactant particles delivered to the lungs of the patient. By heating the dispersion the amount of phospholipid delivered to the lungs of the patient is increased.The dispersion is comprised of a phospholipid dispersed in an aqueous carrier. In a particular embodiment of the invention, the phospholipid is preferably dipalmitoylphosphatidylcholine (DPPC) included in an amount from about 8 to 50 milligrams per milliliter of aqueous carrier, and the dispersion is preferably heated to a temperature between about 25° C. and 75° C.Other References
| |
